Depersonalization disorder

Summary

Depersonalization disorder (MONDO:0001186) is a disease and 4 clinical trials. Top therapeutic interventions include fluoxetine. A subtype of dissociative disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	depersonalization disorder
Mondo ID	MONDO:0001186
DOID	DOID:11038
NCIT	C94331
SNOMED CT	70764005
UMLS	C0683416
MedGen	151919
Is cancer (heuristic)	no

Disease family

This is a subtype of dissociative disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › dissociative disorder › depersonalization disorder

Related subtypes (2): multiple personality disorder, dissociative amnesia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00529217	PHASE2	COMPLETED	Treatment of Depersonalization Disorder With Transcranial Magnetic Stimulation (TMS)
NCT02256085	PHASE2	WITHDRAWN	Treatment of Depersonalization Disorder With Repetitive Transcranial Magnetic Stimulation (rTMS)
NCT00004446	Not specified	COMPLETED	Study of Fluoxetine in Patients With Depersonalization Disorder
NCT02476435	Not specified	COMPLETED	Depersonalization Disorder: Therapeutic Effect of Neuronavigated Repetitive Transcranial Stimulation

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
FLUOXETINE	4	1